JPH08301363A - Packaging bag for liquid medicine - Google Patents
Packaging bag for liquid medicineInfo
- Publication number
- JPH08301363A JPH08301363A JP7108488A JP10848895A JPH08301363A JP H08301363 A JPH08301363 A JP H08301363A JP 7108488 A JP7108488 A JP 7108488A JP 10848895 A JP10848895 A JP 10848895A JP H08301363 A JPH08301363 A JP H08301363A
- Authority
- JP
- Japan
- Prior art keywords
- group
- packaging bag
- liquid preparation
- alkyl group
- lower alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000007788 liquid Substances 0.000 title claims abstract description 62
- 238000004806 packaging method and process Methods 0.000 title claims abstract description 56
- 239000003814 drug Substances 0.000 title claims abstract description 25
- 239000006097 ultraviolet radiation absorber Substances 0.000 claims abstract description 19
- 229920005989 resin Polymers 0.000 claims abstract description 5
- 239000011347 resin Substances 0.000 claims abstract description 5
- 238000002360 preparation method Methods 0.000 claims description 53
- 125000000217 alkyl group Chemical group 0.000 claims description 30
- -1 benzophenone compound Chemical class 0.000 claims description 21
- 239000000463 material Substances 0.000 claims description 19
- 125000003282 alkyl amino group Chemical group 0.000 claims description 18
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 16
- 229940079593 drug Drugs 0.000 claims description 15
- 238000002834 transmittance Methods 0.000 claims description 15
- 125000005843 halogen group Chemical group 0.000 claims description 12
- 239000004840 adhesive resin Substances 0.000 claims description 11
- 229920006223 adhesive resin Polymers 0.000 claims description 11
- 239000000853 adhesive Substances 0.000 claims description 10
- 239000003242 anti bacterial agent Substances 0.000 claims description 10
- 239000004698 Polyethylene Substances 0.000 claims description 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 8
- 229920000573 polyethylene Polymers 0.000 claims description 8
- 125000003277 amino group Chemical group 0.000 claims description 7
- 239000012669 liquid formulation Substances 0.000 claims description 7
- 229940072132 quinolone antibacterials Drugs 0.000 claims description 7
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 5
- 239000004743 Polypropylene Substances 0.000 claims description 5
- 230000004075 alteration Effects 0.000 claims description 5
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims description 5
- 229920001155 polypropylene Polymers 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- YSLIPUSJNFIFAB-UHFFFAOYSA-N 2-oxopyridine-1-carboxylic acid Chemical group OC(=O)N1C=CC=CC1=O YSLIPUSJNFIFAB-UHFFFAOYSA-N 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 4
- 239000005038 ethylene vinyl acetate Substances 0.000 claims description 4
- 239000011521 glass Substances 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 4
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- 125000004434 sulfur atom Chemical group 0.000 claims description 4
- 239000012965 benzophenone Substances 0.000 claims description 3
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 claims description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
- 229920003002 synthetic resin Polymers 0.000 claims description 3
- 239000000057 synthetic resin Substances 0.000 claims description 3
- 125000002252 acyl group Chemical group 0.000 claims description 2
- 125000004442 acylamino group Chemical group 0.000 claims description 2
- 125000003342 alkenyl group Chemical group 0.000 claims description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 2
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 claims description 2
- 125000001118 alkylidene group Chemical group 0.000 claims description 2
- 125000001691 aryl alkyl amino group Chemical group 0.000 claims description 2
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 229960003405 ciprofloxacin Drugs 0.000 claims description 2
- 125000004122 cyclic group Chemical group 0.000 claims description 2
- 125000000623 heterocyclic group Chemical group 0.000 claims description 2
- 125000001841 imino group Chemical group [H]N=* 0.000 claims description 2
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 2
- 229920002554 vinyl polymer Polymers 0.000 claims description 2
- 230000006866 deterioration Effects 0.000 claims 1
- 239000010410 layer Substances 0.000 description 41
- 239000000243 solution Substances 0.000 description 13
- 238000003860 storage Methods 0.000 description 12
- 230000001070 adhesive effect Effects 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 7
- 229910052782 aluminium Inorganic materials 0.000 description 6
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 5
- 229920000139 polyethylene terephthalate Polymers 0.000 description 5
- 239000005020 polyethylene terephthalate Substances 0.000 description 5
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 239000002985 plastic film Substances 0.000 description 4
- 229920006255 plastic film Polymers 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000011888 foil Substances 0.000 description 3
- 229920001610 polycaprolactone Polymers 0.000 description 3
- 239000004632 polycaprolactone Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000004721 Polyphenylene oxide Substances 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 229920001328 Polyvinylidene chloride Polymers 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- KKEYFWRCBNTPAC-UHFFFAOYSA-N Terephthalic acid Chemical compound OC(=O)C1=CC=C(C(O)=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-N 0.000 description 2
- 239000006096 absorbing agent Substances 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 150000002009 diols Chemical class 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- QQVIHTHCMHWDBS-UHFFFAOYSA-N isophthalic acid Chemical compound OC(=O)C1=CC=CC(C(O)=O)=C1 QQVIHTHCMHWDBS-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000010030 laminating Methods 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000005022 packaging material Substances 0.000 description 2
- 229920000570 polyether Polymers 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 229920001451 polypropylene glycol Polymers 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 239000005033 polyvinylidene chloride Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- ZCSWOYDEEZMOMR-UHFFFAOYSA-N 1-ethyl-6-fluoro-7-methyl-4-oxoquinoline-3-carboxylic acid Chemical compound FC1=C(C)C=C2N(CC)C=C(C(O)=O)C(=O)C2=C1 ZCSWOYDEEZMOMR-UHFFFAOYSA-N 0.000 description 1
- XNIVKSPSCYJKBL-UHFFFAOYSA-N 2h-1,2-benzoxazine-6-carboxylic acid Chemical compound O1NC=CC2=CC(C(=O)O)=CC=C21 XNIVKSPSCYJKBL-UHFFFAOYSA-N 0.000 description 1
- OHXPGWPVLFPUSM-KLRNGDHRSA-N 3,7,12-trioxo-5beta-cholanic acid Chemical compound C1CC(=O)C[C@H]2CC(=O)[C@H]3[C@@H]4CC[C@H]([C@@H](CCC(O)=O)C)[C@@]4(C)C(=O)C[C@@H]3[C@]21C OHXPGWPVLFPUSM-KLRNGDHRSA-N 0.000 description 1
- UPMLOUAZCHDJJD-UHFFFAOYSA-N 4,4'-Diphenylmethane Diisocyanate Chemical compound C1=CC(N=C=O)=CC=C1CC1=CC=C(N=C=O)C=C1 UPMLOUAZCHDJJD-UHFFFAOYSA-N 0.000 description 1
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 1
- DPSPPJIUMHPXMA-UHFFFAOYSA-N 9-fluoro-5-methyl-1-oxo-6,7-dihydro-1H,5H-pyrido[3,2,1-ij]quinoline-2-carboxylic acid Chemical compound C1CC(C)N2C=C(C(O)=O)C(=O)C3=C2C1=CC(F)=C3 DPSPPJIUMHPXMA-UHFFFAOYSA-N 0.000 description 1
- 102100033806 Alpha-protein kinase 3 Human genes 0.000 description 1
- 101710082399 Alpha-protein kinase 3 Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 239000005057 Hexamethylene diisocyanate Substances 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- KYIMHWNKQXQBDG-UHFFFAOYSA-N N=C=O.N=C=O.CCCCCC Chemical compound N=C=O.N=C=O.CCCCCC KYIMHWNKQXQBDG-UHFFFAOYSA-N 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FGDQGIKMWOAFIK-UHFFFAOYSA-N acetonitrile;phosphoric acid Chemical compound CC#N.OP(O)(O)=O FGDQGIKMWOAFIK-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000012790 adhesive layer Substances 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 150000008378 aryl ethers Chemical class 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical group C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 1
- 239000012964 benzotriazole Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- DIOIOSKKIYDRIQ-UHFFFAOYSA-N ciprofloxacin hydrochloride Chemical compound Cl.C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 DIOIOSKKIYDRIQ-UHFFFAOYSA-N 0.000 description 1
- 229960002997 dehydrocholic acid Drugs 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- LVTYICIALWPMFW-UHFFFAOYSA-N diisopropanolamine Chemical compound CC(O)CNCC(C)O LVTYICIALWPMFW-UHFFFAOYSA-N 0.000 description 1
- 229940043276 diisopropanolamine Drugs 0.000 description 1
- IDYZIJYBMGIQMJ-UHFFFAOYSA-N enoxacin Chemical compound N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 IDYZIJYBMGIQMJ-UHFFFAOYSA-N 0.000 description 1
- 229960002549 enoxacin Drugs 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 239000004715 ethylene vinyl alcohol Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229960000702 flumequine Drugs 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- RRAMGCGOFNQTLD-UHFFFAOYSA-N hexamethylene diisocyanate Chemical compound O=C=NCCCCCCN=C=O RRAMGCGOFNQTLD-UHFFFAOYSA-N 0.000 description 1
- ACCCMOQWYVYDOT-UHFFFAOYSA-N hexane-1,1-diol Chemical compound CCCCCC(O)O ACCCMOQWYVYDOT-UHFFFAOYSA-N 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 239000011229 interlayer Substances 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000004706 metal oxides Chemical class 0.000 description 1
- SLCVBVWXLSEKPL-UHFFFAOYSA-N neopentyl glycol Chemical compound OCC(C)(C)CO SLCVBVWXLSEKPL-UHFFFAOYSA-N 0.000 description 1
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 1
- 229960001180 norfloxacin Drugs 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 229960001699 ofloxacin Drugs 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- JOHZPMXAZQZXHR-UHFFFAOYSA-N pipemidic acid Chemical compound N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CN=C1N1CCNCC1 JOHZPMXAZQZXHR-UHFFFAOYSA-N 0.000 description 1
- 229960001732 pipemidic acid Drugs 0.000 description 1
- RCIMBBZXSXFZBV-UHFFFAOYSA-N piromidic acid Chemical compound N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CN=C1N1CCCC1 RCIMBBZXSXFZBV-UHFFFAOYSA-N 0.000 description 1
- 229960004444 piromidic acid Drugs 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920013716 polyethylene resin Polymers 0.000 description 1
- 229920005672 polyolefin resin Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- HRQDCDQDOPSGBR-UHFFFAOYSA-M sodium;octane-1-sulfonate Chemical compound [Na+].CCCCCCCCS([O-])(=O)=O HRQDCDQDOPSGBR-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 229920005992 thermoplastic resin Polymers 0.000 description 1
- DVKJHBMWWAPEIU-UHFFFAOYSA-N toluene 2,4-diisocyanate Chemical compound CC1=CC=C(N=C=O)C=C1N=C=O DVKJHBMWWAPEIU-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 239000002966 varnish Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Landscapes
- Packages (AREA)
- Laminated Bodies (AREA)
Abstract
Description
【０００１】[0001]
【産業上の利用分野】本発明は注射剤や点滴剤等の入っ
た液状製剤袋あるいは容器のための包装袋に関する。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a packaging bag for liquid preparation bags or containers containing injections, drip infusions and the like.
【０００２】[0002]
【従来の技術】一般に、紫外線によって変質しやすい薬
品を包装する場合には、紫外線紫外線遮蔽性の優れた包
装材料が望まれている。ところで、製剤と溶解液の２種
類を別々に包装、搬出、保存する等の製造上、保存上に
不便さを有し、かつ使用するに際して製剤を溶解液に溶
解させるのに手間がかかる粉末製剤よりも、そのような
問題のない液状製剤の方が注射剤や点滴剤としては適し
ている。しかし液状製剤は粉末製剤に比較して長期保存
時の安定性が問題となる。かかる液状製剤の保存時の安
定性のためにも紫外線遮蔽性に優れた包装材料が望まれ
ている。2. Description of the Related Art Generally, when packaging chemicals that are easily deteriorated by ultraviolet rays, a packaging material having excellent ultraviolet and ultraviolet shielding properties is desired. By the way, a powder formulation which has inconvenience in production and storage, such as packaging, unloading, and storing two types of a formulation and a solution separately, and which takes time to dissolve the formulation in the solution when used. Rather, a liquid preparation without such a problem is more suitable as an injection or drip. However, liquid formulations have a problem with stability during long-term storage as compared with powder formulations. There is a demand for a packaging material having an excellent UV-shielding property for the stability of such a liquid preparation during storage.
【０００３】紫外線遮蔽性に優れた材料として、従来は
プラスチックフィルムにアルミ箔を貼り合わせたものが
主に使用されていた。プラスチックフィルムにアルミ箔
を貼り合わせたものは、紫外線の遮蔽性の点では優れて
いるが、不透明であるために、内容物が外から見えず、
そのため内容物が変質を受けたか否かが開封するまで分
からないという問題があった。As a material excellent in ultraviolet shielding property, a material obtained by laminating an aluminum foil on a plastic film has been mainly used conventionally. A plastic film laminated with aluminum foil is excellent in terms of blocking ultraviolet rays, but it is opaque, so the contents cannot be seen from the outside,
Therefore, there is a problem that it is not known whether the contents have been altered or not until it is opened.
【０００４】また紫外線遮蔽材料として、上記のプラス
チックフィルムにアルミ箔を貼り合わせたもの以外に、
白色等に着色したプラスチックフィルムを積層したもの
や、フィルムの製膜時に紫外線吸収剤を練り込んだ紫外
線カットフィルム（例えば、ダイセル化学（株）：セネ
ジＫＯＰ−ＵＶ）が知られている。前者は紫外線遮蔽性
を満足する程度の着色とすると内容物が透視できなくな
り、後者は最も紫外線透過率が低い３５０〜３６０ｎｍ
付近でも１０〜１５％の透過率であり、特に３８０〜３
９０ｎｍ付近では２５〜４０％程度の透過率となり、満
足する程度の紫外線遮蔽性を得ることができないなどの
欠点がある。もし紫外線遮蔽性を上げるために製膜時に
有効量の紫外線吸収剤を練り込むと、フィルム自体が脆
くなる問題があり、また紫外線吸収剤が熱にも弱いため
満足する物性のフィルムを得ることが不可能である。As the ultraviolet shielding material, other than the above-mentioned plastic film laminated with aluminum foil,
Known are laminates of plastic films colored in white or the like, and ultraviolet cut films in which an ultraviolet absorber is kneaded at the time of film formation (for example, Daicel Chemical Industries, Ltd .: Seneji KOP-UV). If the former is colored to the extent that the ultraviolet shielding property is satisfied, the contents cannot be seen through, and the latter has the lowest ultraviolet transmittance of 350 to 360 nm.
Even in the vicinity, the transmittance is 10 to 15%, especially 380 to 3
In the vicinity of 90 nm, the transmittance is about 25 to 40%, and there is a drawback that it is not possible to obtain a satisfactory ultraviolet shielding property. If an effective amount of an ultraviolet absorber is kneaded during film formation to improve the ultraviolet shielding property, there is a problem that the film itself becomes brittle, and the ultraviolet absorber is also weak against heat, so that a film having satisfactory physical properties may be obtained. It is impossible.
【０００５】[0005]
【発明が解決しようとする課題】本発明は上記事情に鑑
みなされたものであり、紫外線を遮蔽するとともに内容
物を透視可能な液状製剤用包装袋を提供することを目的
とする。SUMMARY OF THE INVENTION The present invention has been made in view of the above circumstances, and an object of the present invention is to provide a liquid preparation packaging bag that shields ultraviolet rays and allows the contents to be seen through.
【０００６】[0006]
【課題を解決するための手段】すなわち本発明は基材層
と熱接着性樹脂層とを紫外線吸収剤を含有する中間層を
介して貼り合わせた積層シートを前記熱接着性樹脂層を
内面として接着することにより構成される包装袋であっ
て、内容物を透視可能とすることを特徴とする、液状製
剤の入った袋あるいは容器を包装するための液状製剤用
包装袋に関する。本発明の液状製剤用包装袋は基材層と
熱接着性樹脂層とを紫外線吸収剤を含有する中間層を介
して貼り合わせた３層構成からなる。That is, according to the present invention, a laminated sheet in which a base material layer and a heat-adhesive resin layer are bonded together via an intermediate layer containing an ultraviolet absorber, with the heat-adhesive resin layer as an inner surface, is provided. The present invention relates to a packaging bag for bonding a liquid formulation, which is characterized by allowing the contents to be seen through, and a packaging bag for a liquid formulation for packaging a bag or a container containing the liquid formulation. The liquid preparation packaging bag of the present invention has a three-layer structure in which a base material layer and a heat-adhesive resin layer are bonded together via an intermediate layer containing an ultraviolet absorber.
【０００７】本発明において熱接着性樹脂層とは液状製
剤用包装袋の内側の層をいい、液状製剤が入れられる側
の層をいう。熱接着性樹脂層の材質は可視光透過性であ
る樹脂であれば特に限定されず、一般にはポリエチレン
（ＰＥ）、ポリプロピレン（ＰＰ）等のポリオレフィン
系樹脂、またはそれら以外にもエチレン酢酸ビニル共重
合体（ＥＶＡ）等の熱可塑性樹脂が使用され、後述する
中間層、基材層との接着性、または内容物の重量等によ
る接着強度等を考慮して適宜選択される。In the present invention, the heat-adhesive resin layer means the inner layer of the packaging bag for liquid preparations, and the layer on the side where the liquid preparations are put. The material of the heat-adhesive resin layer is not particularly limited as long as it is a resin that transmits visible light, and is generally a polyolefin resin such as polyethylene (PE) or polypropylene (PP), or ethylene vinyl acetate copolymer A thermoplastic resin such as a combination (EVA) is used, and is appropriately selected in consideration of the adhesiveness with the intermediate layer and the base material layer described later, the adhesive strength due to the weight of the contents, and the like.
【０００８】本発明において基材層とは液状製剤用包装
袋の外側、すなわち液状製剤が入れられる側と反対側の
層をいう。該層の材質は可視光透過性であれば特に限定
されないが、ある程度外部からの衝撃を受けても傷がつ
かないものが望ましく、例えば延伸ポリエチレンテレフ
タレート（ＰＥＴ）、延伸ポリプロピレン（ＯＰＰ）、
延伸ナイロン（ＯＮＹ）等が使用される。In the present invention, the base material layer means the layer on the outside of the packaging bag for liquid preparations, that is, on the side opposite to the side where the liquid preparations are placed. The material of the layer is not particularly limited as long as it is transparent to visible light, but it is desirable that it is not damaged even if an external impact is applied to some extent. For example, stretched polyethylene terephthalate (PET), stretched polypropylene (OPP),
Stretched nylon (ONY) or the like is used.
【０００９】基材層には酸素バリアー性を付与してもよ
く、上記に例示したものの内側表面にポリ塩化ビニリデ
ン樹脂（ＰＶＤＣ）をコーティングしたもの（Ｋ−ＰＥ
Ｔ、Ｋ−ＯＰＰ、Ｋ−ＯＮＹ等）、あるいはシリカ等の
金属酸化物を蒸着したものを使用してもよいし、または
該基材層にエチレンビニルアルコール（ＥＶＯＨ）やポ
リビニルアルコール（ＰＶＡ）等の層を積層したもので
もよい。An oxygen barrier property may be imparted to the base material layer, and the inner surface of the above-exemplified material is coated with polyvinylidene chloride resin (PVDC) (K-PE).
T, K-OPP, K-ONY, etc.) or a metal oxide such as silica vapor-deposited may be used, or ethylene vinyl alcohol (EVOH), polyvinyl alcohol (PVA), etc. may be used for the base material layer. It may be a laminate of layers.
【００１０】上記基材層と熱接着性樹脂層は紫外線吸収
剤を含有する中間層により貼り合わされる。中間層に使
用される紫外線吸収剤としては２−ヒドロオキシベンゾ
フェノン、２，４−ジヒドロオキシベンゾフェノン等の
ベンゾフェノン系化合物、またはベンゾトリアゾール系
化合物等が使用可能である。これらの紫外線吸収剤は単
独で用いてもよいし、２種以上組み合わせてもよく、中
間層中に０．５〜０．８ｇ／ｍ2の範囲の割合で含有さ
せるようにするのが好ましく、さらに０．５５〜０．８
ｇ／ｍ2の範囲がより好ましいものである。この範囲と
することにより安定した層間強度および紫外線遮断率が
得られる可能性が高くなるものである。The base material layer and the heat-adhesive resin layer are bonded together by an intermediate layer containing an ultraviolet absorber. As the ultraviolet absorber used in the intermediate layer, a benzophenone compound such as 2-hydrooxybenzophenone or 2,4-dihydrooxybenzophenone, or a benzotriazole compound can be used. These ultraviolet absorbers may be used alone or in combination of two or more, and it is preferable that they are contained in the intermediate layer in a ratio of 0.5 to 0.8 g / m 2 . 0.55-0.8
The range of g / m 2 is more preferable. Within this range, there is a high possibility that stable interlayer strength and UV blocking rate can be obtained.
【００１１】上記紫外線吸収剤を含有する中間層による
基材層と熱接着性樹脂層との貼り合わせは、適当な接着
剤に紫外線吸収剤を含有させた接着剤により、接着剤層
を形成することにより行ってもよい。この場合に使用さ
れる接着剤は、層形成後に可視光を透過するものから選
択されるが、例えば本発明に使用可能な接着剤としては
芳香族−エーテル系、エステル系、脂肪族−エーテル
系、エステル系の二液硬化タイプのウレタン系接着剤等
が使用できる。その接着剤の具体例としては、主剤とし
て、ポリエチレングリコール、ポリプロピレングリコー
ル、ポリテトラメチレングリコール、エチレンオキサイ
ドプロピレンオキサイド共重合体、ポリエチレングリコ
ールポリカプロラクトン共重合体、ポリプロピレングリ
コールポリカプロラクトン共重合体、ポリテトラメチレ
ングリコールポリカプロラクトン共重合体、ポリエチレ
ングリコールポリバレロラクトン共重合体などのポリエ
ーテルポリオールや、エチレングリコール、プロピレン
グリコール、ブタンジオール、ヘキサンジオール、ネオ
ペンチルグリコール、ダイマージオールなどのジオール
類とアジピン酸、セバチン酸、アゼライン酸、イソフタ
ル酸、テレフタル酸、マレイン酸、フマル酸、ダイマー
酸などの２塩基酸類からなるポリエステルポリオールが
用いられ、また硬化剤としては、トリレンジイソシアネ
ート、ジフェニルメタンジイソシアネート、ヘキサメチ
レンジイソシアネートなどの芳香族ジイソシアネート化
合物や、ヘキサンメチレンジイソシアネートなどの脂肪
族ジイソシアネート化合物などを使用することができ
る。For the bonding of the base material layer and the heat-adhesive resin layer with the intermediate layer containing the ultraviolet absorber, the adhesive layer is formed by the adhesive containing the ultraviolet absorber in an appropriate adhesive. You may go by The adhesive used in this case is selected from those that transmit visible light after the layer is formed, and examples of the adhesive that can be used in the present invention include aromatic-ether-based, ester-based, and aliphatic-ether-based adhesives. An ester-based two-component curing type urethane adhesive or the like can be used. Specific examples of the adhesive include polyethylene glycol, polypropylene glycol, polytetramethylene glycol, ethylene oxide propylene oxide copolymer, polyethylene glycol polycaprolactone copolymer, polypropylene glycol polycaprolactone copolymer, polytetramethylene as the main agent. Polyether polyols such as glycol polycaprolactone copolymer and polyethylene glycol polyvalerolactone copolymer, diols such as ethylene glycol, propylene glycol, butanediol, hexanediol, neopentyl glycol and dimer diol, and adipic acid, sebacic acid Polyester consisting of dibasic acids such as azelaic acid, isophthalic acid, terephthalic acid, maleic acid, fumaric acid and dimer acid Used is ester polyol, as also the curing agent may be used tolylene diisocyanate, diphenylmethane diisocyanate, and aromatic diisocyanate compounds such as hexamethylene diisocyanate, and the like aliphatic diisocyanate compounds such as hexane diisocyanate.
【００１２】中間層は上記した方法のほかにも、予め基
材層の液状製剤が入れられる側に紫外線吸収剤を含有さ
せたワニスをコーティングしておく方法がある。In addition to the above-mentioned method, the intermediate layer may be coated in advance with a varnish containing an ultraviolet absorber on the side of the base material layer into which the liquid preparation is placed.
【００１３】本発明においては最終的に得られる液状製
剤用包装袋は、波長３８０ｎｍの紫外線の透過率が７．
０％以下であり、且つ波長３９０ｎｍの紫外線の透過率
が１７．０％以下であるように構成することが好ましい
ものである。さらには波長３８０ｎｍの紫外線の透過率
が１．０％以下であり、且つ波長３８０ｎｍの紫外線の
透過率が１０．０％以下であるように構成することがよ
り好ましいものである。その特性が得られるように、基
材層、中間層および熱接着性樹脂層の各層の個々の厚さ
を適宜設定すべきであり、その結果として包装袋の厚さ
が決定される。通常その３層の合計厚さは、袋の態様に
もよるが５０〜１５０μｍ程度である。In the present invention, the finally obtained packaging bag for liquid preparation has a transmittance of ultraviolet rays having a wavelength of 380 nm of 7.
It is preferable that the transmittance is 0% or less and the transmittance of ultraviolet rays having a wavelength of 390 nm is 17.0% or less. Further, it is more preferable that the transmittance of ultraviolet rays having a wavelength of 380 nm is 1.0% or less and the transmittance of ultraviolet rays having a wavelength of 380 nm is 10.0% or less. The individual thicknesses of the base material layer, the intermediate layer, and the heat-adhesive resin layer should be appropriately set so that the characteristics can be obtained, and as a result, the thickness of the packaging bag is determined. Usually, the total thickness of the three layers is about 50 to 150 μm, depending on the form of the bag.
【００１４】なお本発明の液状製剤用包装袋は、柔軟性
のあるフィルムから構成される一般的意味での袋の態様
および柔軟性のない容器をも含むものとする。The packaging bag for liquid preparations of the present invention includes a bag form in the general sense composed of a flexible film and an inflexible container.
【００１５】本発明の液状製剤用包装袋は紫外線で変質
を受けやすい液状製剤、特に注射剤や点滴液の入った袋
あるいは容器を包装するのに適している。また、用いら
れる医薬品は、液状製剤において紫外線で変質を受けや
すいものであれば、特に限定されるものではない。The packaging bag for a liquid preparation of the present invention is suitable for packaging a liquid preparation which is easily deteriorated by ultraviolet rays, particularly a bag or a container containing an injection or an infusion solution. Further, the drug used is not particularly limited as long as it is a liquid formulation that is susceptible to alteration by ultraviolet rays.
【００１６】特に白色蛍光灯照射時（照射条件は１５０
０ルクス、５０日間）に色差の変動が１以上となる紫外
線で変質を受けやすい液状製剤に対して本発明の包装袋
が有用である。かかる液状製剤を本発明の包装袋に封入
して使用すると、１５００ルクス５０日間、白色蛍光灯
を照射しても液状製剤中の色差の変動を０．５以下に抑
えることができる。Especially when irradiating a white fluorescent lamp (irradiation condition is 150
The packaging bag of the present invention is useful for a liquid preparation which is susceptible to alteration by ultraviolet rays, which has a color difference variation of 1 or more at 0 lux for 50 days. When such a liquid preparation is used by being enclosed in the packaging bag of the present invention, the variation of the color difference in the liquid preparation can be suppressed to 0.5 or less even when irradiated with a white fluorescent lamp for 1,500 lux for 50 days.
【００１７】注射剤や点滴用の液状薬品として、特に例
えばキノリン骨格の６位にフッ素、７位に塩基性アミン
を有するキノロン系抗菌剤のうち、液状製剤において紫
外線で変質を受けやすいもの、例えば下記一般式（Ａ）
あるいは（Ｂ）で表されるピリドンカルボン酸に有用で
ある：As a liquid drug for injections and infusions, for example, among quinolone type antibacterial agents having fluorine at the 6-position and basic amine at the 7-position of the quinoline skeleton, those which are easily deteriorated by ultraviolet rays in the liquid preparation, for example, The following general formula (A)
Alternatively useful for the pyridonecarboxylic acid represented by (B):
【００１８】[0018]
【化４】 ［式中、Ｒ1は置換されていてもよい低級アルキル、低
級アルケニル、シクロアルキル、アリールまたは複素環
式基を；Ｒ2は、水素原子、ハロゲン原子、低級アルキ
ル基、アルコキシ基、保護されていてもよいヒドロキシ
ル、アミノもしくは低級アルキルアミノ基またはジ−低
級アルキルアミノ基を；Ｒ3は、置換されていてもよい
シクロアルキル、ビニルまたは環状アミノ基を；Ａ1は
窒素原子またはＣ−Ｘ1（式中、Ｘ1は、水素原子、ハロ
ゲン原子、またはＲ1と一緒になって式；[Chemical 4] [Wherein R 1 represents an optionally substituted lower alkyl, lower alkenyl, cycloalkyl, aryl or heterocyclic group; R 2 represents a hydrogen atom, a halogen atom, a lower alkyl group, an alkoxy group or a protected group; Optionally a hydroxyl, amino or lower alkylamino group or a di-lower alkylamino group; R 3 is an optionally substituted cycloalkyl, vinyl or cyclic amino group; A 1 is a nitrogen atom or C—X 1 (In the formula, X 1 represents a hydrogen atom, a halogen atom, or R 1 together with a formula;
【化５】 （式中、Ｒ4は、水素原子または低級アルキル基を；Ｄ
は、酸素原子また硫黄原子を示す）で表される基を示
す）を示し；Ｂ1は窒素原子またはＣ−Ｘ2（式中、Ｘ2
は、水素原子またはハロゲン原子を示す）で表される基
を示す）］Embedded image (In the formula, R 4 represents a hydrogen atom or a lower alkyl group; D
Represents a group represented by an oxygen atom or a sulfur atom); and B 1 represents a nitrogen atom or C—X 2 (in the formula, X 2
Represents a hydrogen atom or a halogen atom)))]
【００１９】[0019]
【化６】 ［式中、Ｒ5は、水素原子またはアルキル基を；Ｒ6は、
水素原子、ハロゲン原子、アルコキシ基、ヒドロキシル
基、アルアルキルオキシ基、アミノ基、アルアルキルア
ミノ基、低級アルキルアミノ基またはジ−低級アルキル
アミノ基を；Ｒ7は、水素原子、低級アルキル基、アミ
ノ基、アシルアミノ基、アルアルキルオキシカルボニル
アミノ基、低級アルキルアミノ基、アシル低級アルキル
アミノ基、ジ−低級アルキルアミノ基、カルボキシル
基、アルコキシカルボニル基、アミノ低級アルキル基、
アルコキシカルボニルアミノ低級アルキル基、低級アル
キルアミノ低級アルキル基、ジ−低級アルキルアミノ低
級アルキル基およびヒドロキシ低級アルキル基から選ば
れる１つ以上の基を；Ｒ8は、水素原子、低級アルキル
基、ハロゲノ低級アルキル基、ヒドロキシ低級アルキル
基、テトラヒドロビラニルオキシ低級アルキル基、低級
アルキリデン基、およびＲ4が結合する炭素原子ととも
にシクロアルカン環を形成する基から選ばれる１つ以上
の基を；Ｘ3は、ハロゲン原子を；およびＡ2は、酸素原
子もしくは硫黄原子または低級アルキル基で置換されて
いてもよいイミノ基を、それぞれ示す］。[Chemical 6] [Wherein R 5 is a hydrogen atom or an alkyl group; R 6 is
Hydrogen atom, halogen atom, alkoxy group, hydroxyl group, aralkyloxy group, amino group, aralkylamino group, lower alkylamino group or di-lower alkylamino group; R 7 is hydrogen atom, lower alkyl group, amino Group, acylamino group, aralkyloxycarbonylamino group, lower alkylamino group, acyl lower alkylamino group, di-lower alkylamino group, carboxyl group, alkoxycarbonyl group, amino lower alkyl group,
One or more groups selected from an alkoxycarbonylamino lower alkyl group, a lower alkylamino lower alkyl group, a di-lower alkylamino lower alkyl group and a hydroxy lower alkyl group; R 8 represents a hydrogen atom, a lower alkyl group, a halogeno lower group One or more groups selected from an alkyl group, a hydroxy lower alkyl group, a tetrahydroviranyloxy lower alkyl group, a lower alkylidene group, and a group forming a cycloalkane ring with the carbon atom to which R 4 is bonded; X 3 is A halogen atom; and A 2 represents an oxygen atom, a sulfur atom, or an imino group optionally substituted with a lower alkyl group].
【００２０】なお、上記一般式（Ａ）又は（Ｂ）で表さ
れるピリドンカルボン酸のより具体的な記載は特開平６
−２１１６９５号公報および特公平５−８８７１４号公
報にそれぞれ記載されている。ここに該両公報における
一般式（Ａ）および（Ｂ）で表されるピリドンカルボン
酸に関する記載を本明細書の一部として引用する）。A more specific description of the pyridonecarboxylic acid represented by the above general formula (A) or (B) is described in JP-A-6-26.
-2111695 and Japanese Patent Publication No. 5-88714. The description relating to the pyridonecarboxylic acids represented by the general formulas (A) and (B) in both of these publications is cited as a part of the present specification).
【００２１】さらには、シノキサシン、オキソリン酸、
フルメキン、ピロミド酸、ピペミド酸、ナルジクス酸、
ノルフロキサシン、オフロキサシン、シプロフロキサシ
ン、エノキサシン等の抗菌剤およびそれらと塩を形成す
る化合物、例えば塩酸、ホウ酸、炭酸、乳酸、メタンス
ルホン酸、プロピオン酸、コハク酸、胆汁酸、デヒドロ
コール酸、硫酸、リン酸、フマル酸等の酸、水酸化カリ
ウム、水酸化ナトリウム、エタノールアミン、リジン、
アルギニン（塩基性アミノ酸）、Ｎ−メチルグルカミ
ン、トロメタモール、ジイソプロパノールアミン、メグ
ルミン等の塩基とともに含まれている。それらの組成物
中キノロン系抗菌剤が紫外線により変質を受けやすい
が、本発明の包装袋によりその弊害が防止される。当該
液状薬品中に上記の化合物が０．１〜１００ｍｇ／ｍｌ
程度の濃度で含有させればよい。その際のｐＨ、浸透圧
比は生理的に許容される条件であれば特に限定されな
い。例えば、ｐＨとしては２〜１１程度、浸透圧比とし
ては０．５〜５程度が例示される。また、製剤学的に既
知の添加剤、安定化剤、溶解補助剤あるいは等張化剤等
を添加してもよい。例えば、塩化ナトリウム、ブドウ糖
等が例示される。Further, sinoxacin, oxophosphate,
Flumequine, pyromidic acid, pipemidic acid, naldixic acid,
Norfloxacin, ofloxacin, ciprofloxacin, compounds such as enoxacin and salts forming with them, such as hydrochloric acid, boric acid, carbonic acid, lactic acid, methanesulfonic acid, propionic acid, succinic acid, bile acid, dehydrocholic acid, Acids such as sulfuric acid, phosphoric acid, fumaric acid, potassium hydroxide, sodium hydroxide, ethanolamine, lysine,
It is contained with a base such as arginine (basic amino acid), N-methylglucamine, trometamol, diisopropanolamine, meglumine. The quinolone antibacterial agents in these compositions are susceptible to alteration by ultraviolet rays, but the adverse effect is prevented by the packaging bag of the present invention. 0.1 to 100 mg / ml of the above compound in the liquid chemical
It may be contained at a concentration of about. The pH and osmotic pressure ratio at that time are not particularly limited as long as they are physiologically acceptable. For example, the pH is about 2 to 11, and the osmotic pressure ratio is about 0.5 to 5, for example. Further, pharmaceutically known additives, stabilizers, solubilizing agents, tonicity agents, etc. may be added. For example, sodium chloride, glucose, etc. are illustrated.
【００２２】上記の注射剤や点滴用の液状製剤はポリエ
チレン、ポリプロピレン、エチレン−酢酸ビニル共重合
体等の合成樹脂あるいはガラス等で形成される袋あるい
は容器に、投与量一回分の医薬品に相当する１０〜１０
０００ｍｇ程度が充填される。充填される液量としては
０．５〜２０００ｍｌ程度が例示される。The above-mentioned injections or liquid preparations for infusion correspond to a single dose of a medicine in a bag or container formed of synthetic resin such as polyethylene, polypropylene, ethylene-vinyl acetate copolymer or glass, or the like. 10 to 10
About 000 mg is filled. The amount of liquid to be filled is, for example, about 0.5 to 2000 ml.
【００２３】このように注射剤や点滴用の液状製剤の充
填された袋あるいは容器が、本発明の液状製剤用包装袋
に一つずつあるいは複数単位で包装される。このとき、
袋あるいは容器とともに脱酸素剤を添付してもよい。ま
た、このように包装された袋を、包装状態で加熱滅菌処
理を行ってもよい。The bag or container filled with the liquid preparation for injection or drip in this manner is packaged one by one or in plural units in the packaging bag for liquid preparation of the present invention. At this time,
An oxygen absorber may be attached together with the bag or container. Further, the bag thus packaged may be subjected to heat sterilization treatment in a packaged state.
【００２４】以下、本発明をさらに具体的実施例を用い
て説明する。The present invention will be described below in more detail with reference to specific examples.
【００２５】実施例１ （１）薬液の調製 (S)-10-(1-アミノシクロプロピル)-9-フルオロ-3-メチ
ル-7-オキソ-2,3-ジヒドロ-7H-ピリド[1,2,3-de][1,4]
ベンズオキサジン-6-カルボン酸５００ｍｇ、メタンス
ルホン酸１５０ｍｇおよび塩化ナトリウム９００ｍｇを
注射用蒸留水に溶解し、全量を１０００ｍｌとした。 Example 1 (1) Preparation of chemical solution (S) -10- (1-aminocyclopropyl) -9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido [1, 2,3-de] [1,4]
500 mg of benzoxazine-6-carboxylic acid, 150 mg of methanesulfonic acid and 900 mg of sodium chloride were dissolved in distilled water for injection to make the total amount 1000 ml.
【００２６】（２）薬液容器（内袋）への充填 上記で調製した液状製剤を薬液容器（１００ｍｌ容）に
充填した。該薬液容器は日局輸液用プラスチック容器
（ポリエチレン製ソフトバッグ）を用いた。(2) Filling into a liquid medicine container (inner bag) The liquid preparation prepared above was filled into a liquid medicine container (100 ml volume). As the drug solution container, a plastic container (polyethylene soft bag) for Japanese Pharmacopoeia infusion was used.
【００２７】（３）液状製剤用包装袋（外袋）による包
装 厚さ１２μｍのポリエチレンテレフタレートフィルム
（ＰＥＴ）、中間層および厚さ４０μｍのポリエチレン
フィルム（ＰＥ）からなる容量２００ｍｌの包装袋中
に、上記の薬液容器を包装した。なお中間層はベンゾフ
ェノン系紫外線吸収剤（大日精化工業（株）：Ｌ−０
２）をポリエーテルポリウレタン系接着剤（大日精化工
業（株）：主剤−セイカボンドＡ−１８８、硬化剤−セ
イカボンドＣ−８９による二液硬化タイプ）に添加し、
ＰＥＴ基材層とＰＥ層とを接着させたもので、グラビア
ロールによるドライラミネート方法により厚さ１μｍに
形成させたものである。包装袋の紫外線遮蔽効果および
透明性を、中間層の紫外線吸収剤の含有量を変化させ実
験例１〜３のように評価した。(3) Packaging with packaging bag (outer bag) for liquid preparation In a packaging bag with a capacity of 200 ml, which comprises a polyethylene terephthalate film (PET) having a thickness of 12 μm, an intermediate layer and a polyethylene film (PE) having a thickness of 40 μm, The above drug solution container was packaged. The intermediate layer is a benzophenone-based ultraviolet absorber (Daini Seika Kogyo KK: L-0).
2) is added to a polyether polyurethane adhesive (Dainichi Seika Kogyo Co., Ltd .: two-component curing type consisting of main agent-SEICABOND A-188 and curing agent-SEICABOND C-89),
The PET base material layer and the PE layer are adhered to each other and are formed to have a thickness of 1 μm by a dry laminating method using a gravure roll. The ultraviolet shielding effect and the transparency of the packaging bag were evaluated as in Experimental Examples 1 to 3 by changing the content of the ultraviolet absorber in the intermediate layer.
【００２８】実施例２ （１）薬液の調製 １−シクロプロピル−６−フルオロ−１，４−ジヒドロ
−４−オキソ−７−（１−ピペラジニル）−３−キノリ
ンカルボン酸（一般的シプロフロキサシン）２００ｍｇ
およびブドウ糖５００ｍｇを注射用蒸留水に溶解し、全
量を１００ｍｌとした。Example 2 (1) Preparation of Chemical Solution 1-Cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7- (1-piperazinyl) -3-quinolinecarboxylic acid (general ciprofloxy) 200 mg
And 500 mg of glucose were dissolved in distilled water for injection to make the total amount 100 ml.
【００２９】（２）薬液容器への充填 （１）で調製した液状製剤１６ｍｌを、薬液容器（２０
ｍｌ容）に充填した。該薬液容器は日局注射剤用ガラス
容器（ガラスバイアル）を用いた。(2) Filling into the drug solution container 16 ml of the liquid preparation prepared in (1) was added to the drug solution container (20
ml volume). As the drug solution container, a glass container (glass vial) for Japanese Pharmacopoeia injection was used.
【００３０】（３）液状製剤用包装袋による包装 上記実施例１（３）に開示された［検体−−３］、ただ
し、容量は５０ｍｌを用いて包装を行った。(3) Packaging with a packaging bag for liquid preparation [Sample-3] disclosed in Example 1 (3) above, except that the volume was 50 ml.
【００３１】[0031]
【評価】実験例１ 液状製剤用包装袋中の紫外線遮断剤の含有率と紫外線透
過率および長期保存時の安定化効果の関係を検討した。
紫外線透過率は３８０ｎｍおよび３９０ｎｍ、紫外線の
透過率を測定した。結果を表１に示した。ケミカルラン
プ直下２０ｃｍで１４日間保存した。その後、薬液容器
中の薬液を取り出し、分光色彩計を用いて可視光線領域
における全波長での吸光度の差（保存後の値−保存直前
の値）で評価し、色差として表１中に示した。なお、分
光色彩計はＣＬＲ−７１００Ｆ（島津製作所製）を用い
た。測定条件は透過光、Ｄ６５／１０度視野とした。ま
た、標準校正には生理食塩液を用いた。[Evaluation] Experimental Example 1 The relationship between the content of the ultraviolet blocking agent in the packaging bag for liquid preparation, the ultraviolet transmittance, and the stabilizing effect during long-term storage was examined.
The ultraviolet transmittance was 380 nm and 390 nm, and the ultraviolet transmittance was measured. The results are shown in Table 1. It was stored at 20 cm directly under the chemical lamp for 14 days. Then, the drug solution in the drug solution container was taken out and evaluated by the difference in absorbance at all wavelengths in the visible light region (value after storage-value immediately before storage) using a spectrocolorimeter, and the color difference is shown in Table 1. . The spectrocolorimeter used was CLR-7100F (manufactured by Shimadzu Corporation). The measurement conditions were transmitted light and a D65 / 10 degree visual field. A physiological saline solution was used for standard calibration.
【００３２】[0032]
【表１】 [Table 1]
【００３３】実験例２ 無包装時、アルミ包装時、本発明での包装時とで長期保
存時の安定化効果の関係を検討した。このときアルミ包
装としては片面にアルミ蒸着を施した厚さ１２μｍの延
伸ポリプロピレンフィルムの該アルミ蒸着面に厚さ４０
μｍのポリエチレン樹脂を押出しラミネートしたものを
使用し、本発明の包装袋としては実施例１における検体
３のものを使用した。 Experimental Example 2 The relationship between the stabilizing effect during long-term storage was examined between unpackaged, aluminum packaged and packaged according to the present invention. At this time, as an aluminum package, a stretched polypropylene film having a thickness of 12 μm and having a thickness of 40 μm on the aluminum vapor-deposited surface is vapor-deposited on one side.
A polyethylene resin extruded and laminated having a thickness of μm was used, and the packaging bag of the present invention used was the one of Sample 3 in Example 1.
【００３４】薬液容器へ充填した液状薬剤を白色蛍光灯
（４０Ｗ、東芝製；１５００ルクス）を用いて、５０日
間保存した。安定性は実施例１と同様に、可視光線領域
における全波長での吸光度の差（保存後の値−保存直前
の値）で評価し、色差として表した。結果を表２に示
す。The liquid medicine filled in the medicine container was stored for 50 days by using a white fluorescent lamp (40 W, manufactured by Toshiba; 1500 lux). In the same manner as in Example 1, the stability was evaluated by the difference in absorbance at all wavelengths in the visible light region (value after storage-value immediately before storage) and expressed as a color difference. Table 2 shows the results.
【００３５】実験例３ 実験例２に準じて実験を行い、その時生じた分解物含量
で評価した。ここで、分解物とは光（紫外線）の照射に
より生成した主薬の分解物の総量を意味し、液体クロマ
トグラフィーにおいて相当するピークとして測定解析し
たものである。カラムはＩｎｅｒｔｓｉｌ ＯＤＳ−２
（ＧＬサイエンス社製）、移動相はアセトニトリル−リ
ン酸混液に１−オクタンスルホン酸ナトリウムを添加し
たものを用い、検出は２５４ｎｍの吸光度によった。結
果を表２に示す。 Experimental Example 3 An experiment was carried out in accordance with Experimental Example 2, and the content of decomposed products generated at that time was evaluated. Here, the decomposed product means the total amount of decomposed products of the main drug produced by irradiation with light (ultraviolet rays), which is measured and analyzed as a corresponding peak in liquid chromatography. Column is Inertsil ODS-2
(Manufactured by GL Sciences Inc.), the mobile phase was a mixture of acetonitrile-phosphoric acid mixed with sodium 1-octanesulfonate, and the detection was based on the absorbance at 254 nm. Table 2 shows the results.
【００３６】[0036]
【表２】 [Table 2]
【００３７】実験例４ 実施例２で調製した液状製剤の包装品をケミカルランプ
（近紫外蛍光灯、主波長約３５７ｎｍ、東芝製）直下３
０ｃｍで３日間保存した。その後、薬液容器中の薬液を
取り出し、分光色彩計を用いて可視光線領域における全
波長での吸光度の差（保存後の値−保存直前の値）で評
価し、色差として表３に示した。また、波長４３０ｎｍ
における吸光度の変化を分光光度計で測定した値を併せ
て示す。 Experimental Example 4 The package of the liquid preparation prepared in Example 2 was placed directly under the chemical lamp (near-UV fluorescent lamp, main wavelength about 357 nm, manufactured by Toshiba) 3
It was stored at 0 cm for 3 days. Then, the drug solution in the drug solution container was taken out and evaluated by a difference in absorbance at all wavelengths in the visible light region (value after storage-value immediately before storage) using a spectrocolorimeter, and the color difference is shown in Table 3. Also, the wavelength is 430 nm
The changes in the absorbance in Table 1 are shown together with the values measured by a spectrophotometer.
【００３８】[0038]
【表３】 [Table 3]
【００３９】[0039]
【発明の効果】本発明の液状製剤用包装袋は、紫外線の
吸収効果がよく、包装されるべき液状製剤の変質が起こ
りにくく、長期保存時の安定性に優れている。特に本発
明の液状製剤用包装袋は厚さ５０〜１５０μｍ、その中
間層に紫外線吸収剤を０．５〜０．８ｇ／ｍ2の割合で
含有させた結果、波長３８０〜３９０ｎｍでの紫外線透
過率が７〜１７％以下と従来のものに比較して充分に低
く設定でき、紫外線遮断効果に優れている。また本発明
の液状製剤用包装袋は可視光線を透過するので、内容物
を目視で確認できる。INDUSTRIAL APPLICABILITY The liquid preparation packaging bag of the present invention has a good effect of absorbing ultraviolet rays, is unlikely to undergo alteration of the liquid preparation to be packaged, and is excellent in stability during long-term storage. In particular, the liquid preparation packaging bag of the present invention has a thickness of 50 to 150 μm, and as a result of containing an ultraviolet absorber in the intermediate layer at a rate of 0.5 to 0.8 g / m 2 , the ultraviolet transmission at a wavelength of 380 to 390 nm is achieved. The ratio is 7 to 17% or less, which can be set to be sufficiently low as compared with the conventional one, and is excellent in the ultraviolet blocking effect. Further, since the liquid preparation packaging bag of the present invention transmits visible light, the contents can be visually confirmed.
───────────────────────────────────────────────────── フロントページの続き (72)発明者 巌 徹 大阪府枚方市招堤大谷２丁目25番１号 株 式会社ミドリ十字中央研究所内 (72)発明者 藤原 文男 大阪府大阪市中央区今橋１丁目３番３号 株式会社ミドリ十字内 (72)発明者 上田 泰生 大阪府枚方市招堤大谷２丁目25番１号 株 式会社ミドリ十字中央研究所内 (72)発明者 井上 徹 京都府京都市右京区太秦上刑部町10番地 大日本印刷株式会社内 ─────────────────────────────────────────────────── ─── Continuation of the front page (72) Toru Iwao, Toru Iwao, 2-25-1, Otani, Tsutsumi Otani, Hirakata City, Osaka Prefecture Midori Cross Central Research Institute Co., Ltd. (72) Fumio Fujiwara, 1 Imabashi, Chuo-ku, Osaka-shi, Osaka Chome 3-3 Midori Jushi Co., Ltd. (72) Inventor Yasushi Ueda 2-25-1 Otani, Tsutsumi Otani, Hirakata City, Osaka Prefecture Midori Cross Central Research Institute Co., Ltd. (72) Toru Inoue Ukyo, Kyoto City Kyoto Prefecture 10 Uzumasa Shangjibu-cho, Ward Ward Dai Nippon Printing Co., Ltd.
Claims (17)
剤を含有する中間層を介して貼り合わせた積層シートを
前記熱接着性樹脂層を内面として構成される包装袋であ
って、内容物を透視可能とすることを特徴とする液状製
剤の入った袋あるいは容器を包装するための液状製剤用
包装袋。1. A packaging bag comprising a laminated sheet, in which a base material layer and a heat-adhesive resin layer are bonded together via an intermediate layer containing an ultraviolet absorber, with the heat-adhesive resin layer as an inner surface. A packaging bag for a liquid preparation for packaging a bag or a container containing a liquid preparation, characterized in that the contents can be seen through.
の透過率が７．０％以下であり、且つ波長３９０ｎｍの
紫外線の透過率が１７．０％以下であることを特徴とす
る請求項１記載の液状製剤用包装袋。2. The laminated sheet has a transmittance of ultraviolet rays having a wavelength of 380 nm of 7.0% or less and a transmittance of ultraviolet rays of a wavelength of 390 nm of 17.0% or less. Packaging bag for liquid formulations.
ｇ／ｍ2の割合で含有されていることを特徴とする請求
項１〜２いずれかに記載の液状製剤用包装袋。3. The ultraviolet absorber in the intermediate layer is 0.5 to 0.8.
Liquid preparations for packaging bag according to any one of claims 1-2, characterized in that it is contained in a proportion of g / m 2.
収剤を０．５〜０．８ｇ／ｍ2の割合で含有する中間層
を介して貼り合わせた積層シートを前記熱接着性樹脂層
を内面として構成される包装袋であって、波長３８０ｎ
ｍの紫外線の透過率が７．０％以下であり、且つ波長３
９０ｎｍの紫外線の透過率が１７．０％以下であること
を特徴とする液状製剤の入った袋あるいは容器を包装す
るための液状製剤用包装袋。4. A laminated sheet comprising a base material layer and a heat-adhesive resin layer bonded together via an intermediate layer containing an ultraviolet absorber in a proportion of 0.5 to 0.8 g / m 2 as the heat-adhesive sheet. A packaging bag having a conductive resin layer as an inner surface, which has a wavelength of 380n.
m ultraviolet ray has a transmittance of 7.0% or less and a wavelength of 3
A packaging bag for a liquid preparation for packaging a bag or a container containing the liquid preparation, which has a transmittance of 90 nm ultraviolet rays of 17.0% or less.
である請求項１〜４いずれかに記載の液状製剤用包装
袋。5. The packaging bag for a liquid preparation according to claim 1, wherein the ultraviolet absorber is a benzophenone compound.
り、白色蛍光灯照射時（照射条件は１５００ルクス、５
０日間）に液状製剤の色差の変動が０．５以下である請
求項１〜５いずれかに記載の液状製剤用包装袋。6. By using the packaging bag for liquid preparation, white fluorescent lamp irradiation (irradiation conditions are 1500 lux, 5
The packaging bag for a liquid preparation according to any one of claims 1 to 5, wherein the variation in color difference of the liquid preparation is 0.5 or less in 0 days).
製である請求項１〜６いずれかに記載の液状製剤用包装
袋。7. The packaging bag for liquid preparation according to claim 1, wherein the bag or container is made of synthetic resin or glass.
ンまたはエチレン−酢酸ビニル共重合体である請求項７
記載の液状製剤用包装袋。8. The synthetic resin is polyethylene, polypropylene or an ethylene-vinyl acetate copolymer.
The packaging bag for the liquid preparation described.
薬品を含有してなる請求項１〜８いずれかに記載の液状
製剤用包装袋。9. The packaging bag for a liquid preparation according to claim 1, wherein the liquid preparation contains a drug which is susceptible to deterioration by ultraviolet rays.
包袋の場合、白色蛍光灯照射時（照射条件は１５００ル
クス、５０日間）に色差の変動が１以上となるものであ
る請求項９記載の液状製剤用包装袋。10. The drug, which is susceptible to alteration by ultraviolet rays, has a color difference variation of 1 or more when irradiated with a white fluorescent lamp (irradiation condition is 1500 lux, 50 days) in the case of an unwrapped bag. Packaging bag for liquid formulations.
請求項９記載の液状製剤用包装袋。11. The packaging bag for liquid preparation according to claim 8 or 9, wherein the drug is an antibacterial agent.
項１１記載の液状製剤用包装袋。12. The packaging bag for liquid preparation according to claim 11, wherein the antibacterial agent is a quinolone antibacterial agent.
されるピリドンカルボン酸またはその塩である請求項１
２記載の液状製剤用包装袋； 【化１】 ［式中、Ｒ1は置換されていてもよい低級アルキル、低
級アルケニル、シクロアルキル、アリールまたは複素環
式基を；Ｒ2は、水素原子、ハロゲン原子、低級アルキ
ル基、アルコキシ基、保護されていてもよいヒドロキシ
ル基、アミノ基もしくは低級アルキルアミノ基またはジ
−低級アルキルアミノ基を；Ｒ3は、置換されていても
よいシクロアルキル、ビニルまたは環状アミノ基を；Ａ
1は窒素原子またはＣ−Ｘ1（式中、Ｘ1は、水素原子、
ハロゲン原子、またはＲ1と一緒になって式； 【化２】 （式中、Ｒ4は、水素原子または低級アルキル基を；Ｄ
は、酸素原子また硫黄原子を示す）で表される基を示
す）を示し；Ｂ1は窒素原子またはＣ−Ｘ2（式中、Ｘ2
は、水素原子またはハロゲン原子を示す）で表される基
を示す）］。13. The quinolone antibacterial agent is a pyridonecarboxylic acid represented by the general formula (A) or a salt thereof.
Packaging bag for liquid preparation according to 2; [Wherein R 1 represents an optionally substituted lower alkyl, lower alkenyl, cycloalkyl, aryl or heterocyclic group; R 2 represents a hydrogen atom, a halogen atom, a lower alkyl group, an alkoxy group or a protected group; Optionally a hydroxyl group, an amino group or a lower alkylamino group or a di-lower alkylamino group; R 3 is an optionally substituted cycloalkyl, vinyl or cyclic amino group; A
1 is a nitrogen atom or C—X 1 (wherein, X 1 is a hydrogen atom,
A halogen atom, or R 1 together with the formula; (In the formula, R 4 represents a hydrogen atom or a lower alkyl group; D
Represents a group represented by an oxygen atom or a sulfur atom); and B 1 represents a nitrogen atom or C—X 2 (in the formula, X 2
Represents a hydrogen atom or a halogen atom)).
されるピリドンカルボン酸またはその塩である請求項１
２記載の液状製剤用包装袋： 【化３】 ［式中、Ｒ5は、水素原子またアルキル基を；Ｒ6は、水
素原子、ハロゲン原子、アルコキシ基、ヒドロキシル
基、アルアルキルオキシ基、アミノ基、アルアルキルア
ミノ基、低級アルキルアミノ基またはジ−低級アルキル
アミノ基を；Ｒ7は、水素原子、低級アルキル基、アミ
ノ基、アシルアミノ基、アルアルキルオキシカルボニル
アミノ基、低級アルキルアミノ基、アシル低級アルキル
アミノ基、ジ−低級アルキルアミノ基、カルボキシル
基、アルコキシカルボニル基、アミノ低級アルキル基、
アルコキシカルボニルアミノ低級アルキル基、低級アル
キルアミノ低級アルキル基、ジ−低級アルキルアミノ低
級アルキル基およびヒドロキシ低級アルキル基から選ば
れる１つ以上の基を；Ｒ8は、水素原子、低級アルキル
基、ハロゲノ低級アルキル基、ヒドロキシ低級アルキル
基、テトラヒドロビラニルオキシ低級アルキル基、低級
アルキリデン基、およびＲ4が結合する炭素原子ととも
にシクロアルカン環を形成する基から選ばれる１つ以上
の基を；Ｘ3は、ハロゲン原子を；およびＡ2は、酸素原
子もしくは硫黄原子または低級アルキル基で置換されて
いてもよいイミノ基を、それぞれ示す］。14. The quinolone antibacterial agent is a pyridonecarboxylic acid represented by the general formula (B) or a salt thereof.
Packaging bag for liquid preparation according to 2 above: [Wherein R 5 is a hydrogen atom or an alkyl group; R 6 is a hydrogen atom, a halogen atom, an alkoxy group, a hydroxyl group, an aralkyloxy group, an amino group, an aralkylamino group, a lower alkylamino group or a dialkyl group; A lower alkylamino group; R 7 represents a hydrogen atom, a lower alkyl group, an amino group, an acylamino group, an aralkyloxycarbonylamino group, a lower alkylamino group, an acyl lower alkylamino group, a di-lower alkylamino group, a carboxyl group. Group, alkoxycarbonyl group, amino lower alkyl group,
One or more groups selected from an alkoxycarbonylamino lower alkyl group, a lower alkylamino lower alkyl group, a di-lower alkylamino lower alkyl group and a hydroxy lower alkyl group; R 8 represents a hydrogen atom, a lower alkyl group, a halogeno lower group One or more groups selected from an alkyl group, a hydroxy lower alkyl group, a tetrahydrovillanyloxy lower alkyl group, a lower alkylidene group, and a group forming a cycloalkane ring with the carbon atom to which R 4 is bonded; X 3 is A halogen atom; and A 2 represents an oxygen atom, a sulfur atom, or an imino group optionally substituted with a lower alkyl group].
シクロプロピル)-9-フルオロ-3-メチル-7-オキソ-2,3-
ジヒドロ-7H-ピリド[1,2,3-de][1,4]ベンズオキサジン-
6-カルボン酸またはその塩である請求項１２記載の液状
製剤用包装袋。15. The quinolone antibacterial agent is (S) -10- (1-aminocyclopropyl) -9-fluoro-3-methyl-7-oxo-2,3-
Dihydro-7H-pyrido [1,2,3-de] [1,4] benzoxazine-
The packaging bag for liquid preparation according to claim 12, which is 6-carboxylic acid or a salt thereof.
シクロプロピル)-9-フルオロ-3-メチル-7-オキソ-2,3-
ジヒドロ-7H-ピリド[1,2,3-de][1,4]ベンズオキサジン-
6-カルボン酸のメタンスルホン酸塩である請求項１２記
載の液状製剤用包装袋。16. The quinolone antibacterial agent is (S) -10- (1-aminocyclopropyl) -9-fluoro-3-methyl-7-oxo-2,3-
Dihydro-7H-pyrido [1,2,3-de] [1,4] benzoxazine-
The packaging bag for a liquid preparation according to claim 12, which is a methanesulfonate of 6-carboxylic acid.
ンまたはその塩である請求項１２記載の液状製剤用包装
袋。17. The packaging bag for liquid preparation according to claim 12, wherein the quinolone antibacterial agent is ciprofloxacin or a salt thereof.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP7108488A JPH08301363A (en) | 1995-05-02 | 1995-05-02 | Packaging bag for liquid medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP7108488A JPH08301363A (en) | 1995-05-02 | 1995-05-02 | Packaging bag for liquid medicine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH08301363A true JPH08301363A (en) | 1996-11-19 |
Family
ID=14486041
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP7108488A Pending JPH08301363A (en) | 1995-05-02 | 1995-05-02 | Packaging bag for liquid medicine |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH08301363A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008102822A1 (en) | 2007-02-20 | 2008-08-28 | Fujifilm Corporation | Polymer material containing ultraviolet absorbent |
| WO2008123504A1 (en) | 2007-03-30 | 2008-10-16 | Fujifilm Corporation | Ultraviolet ray absorber composition |
| WO2009022736A1 (en) | 2007-08-16 | 2009-02-19 | Fujifilm Corporation | Heterocyclic compound, ultraviolet ray absorbent, and composition comprising the ultraviolet ray absorbent |
| WO2009123142A1 (en) | 2008-03-31 | 2009-10-08 | 富士フイルム株式会社 | Ultraviolet absorbent compositions |
| WO2009123141A1 (en) | 2008-03-31 | 2009-10-08 | 富士フイルム株式会社 | Ultraviolet absorbent compositions |
| WO2009136624A1 (en) | 2008-05-09 | 2009-11-12 | 富士フイルム株式会社 | Ultraviolet absorbent composition |
-
1995
- 1995-05-02 JP JP7108488A patent/JPH08301363A/en active Pending
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008102822A1 (en) | 2007-02-20 | 2008-08-28 | Fujifilm Corporation | Polymer material containing ultraviolet absorbent |
| WO2008123504A1 (en) | 2007-03-30 | 2008-10-16 | Fujifilm Corporation | Ultraviolet ray absorber composition |
| WO2009022736A1 (en) | 2007-08-16 | 2009-02-19 | Fujifilm Corporation | Heterocyclic compound, ultraviolet ray absorbent, and composition comprising the ultraviolet ray absorbent |
| WO2009123142A1 (en) | 2008-03-31 | 2009-10-08 | 富士フイルム株式会社 | Ultraviolet absorbent compositions |
| WO2009123141A1 (en) | 2008-03-31 | 2009-10-08 | 富士フイルム株式会社 | Ultraviolet absorbent compositions |
| WO2009136624A1 (en) | 2008-05-09 | 2009-11-12 | 富士フイルム株式会社 | Ultraviolet absorbent composition |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10618257B2 (en) | Light-shielding sheet and container | |
| CA2930072C (en) | Multi-layered plastic polymeric container for the storage of pharmaceutical compositions | |
| US5741566A (en) | Autoclavable multilayer films | |
| JP5167392B2 (en) | Chemical container container and method for manufacturing the same | |
| JPS6356449A (en) | Chemically stabilized film | |
| JP4550352B2 (en) | Transparent packaging bag and liquid preparation package packaged outside with this | |
| US20100233326A1 (en) | Antibacterial Laminate | |
| JP4607609B2 (en) | Chemical solution bag, chemical solution bag container, and method for manufacturing chemical solution bag container | |
| JP4335049B2 (en) | Laminated film for infusion bags | |
| US6465062B2 (en) | Light-excluding, multi-layered material | |
| JPH08301363A (en) | Packaging bag for liquid medicine | |
| RU2381103C2 (en) | Container for liquid pharmaceutical compositions with high moistureproof properties | |
| JP4147296B2 (en) | Packaging bag for liquid preparation | |
| KR101185460B1 (en) | Oxygen scavenging composition and method for making same | |
| JP3906455B2 (en) | Multilayer film and its product | |
| EP3094492B1 (en) | Laminated bag for pharmaceuticals | |
| JPS6364742A (en) | Gas barrier laminated film | |
| JPH03289477A (en) | Packaging bag for container receiving medicine container | |
| BR112016018382A2 (en) | anti-scalping pharmaceutical packaging film |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20040902 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040907 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20050111 |